HER2向治疗晚期胃癌的历史和未来
1Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Journal of clinical medicine
|May 27, 2023
概括
人类表皮生长因子受体2 (HER2) 是胃癌的标. 虽然早期的疗法表现有前途,但新的药物一直在扎,但像特拉斯图祖马布德鲁克斯泰克 (trastuzumab deruxtecan) 这样的新疗法可以提供新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 人类表皮生长因子受体2 (HER2) 是一种受体氨酸激酶,在20%的胃和胃食道结癌中过度表达.
- 针对HER2的疗法已经在乳腺癌中取得了成功,在胃癌中也开始了类似的努力.
研究的目的:
- 审查 HER2 向治疗胃和胃食道结癌的时间发展.
- 讨论针对这些癌症的HER2向治疗的挑战和未来方向.
主要方法:
- 对胃和胃食道结癌中HER2向药物的现有文献的综述.
- 治疗开发和临床试验结果的时间分析.
- 胃癌和乳腺癌之间HER2阳性瘤生物学的比较.
主要成果:
- 特拉斯图祖马布是第一个成功的针对胃癌的HER2向药物.
- 与标准疗法相比,随后的药物 (lapatinib,T-DM1,pertuzumab) 并没有改善存活率.
- 特拉斯图祖马布德鲁克斯泰坎代表了最近的进步,表明该领域的进展.
结论:
- 胃癌和乳腺癌之间的内在生物学差异对HER2向治疗的发展构成挑战.
- 尽管有挫折,但像特拉斯图祖马布德鲁克斯泰坎 (trastuzumab deruxtecan) 这样的新药正在推进胃癌的HER2向治疗.
- 胃癌的HER2向治疗的未来是有希望的,正在进行的研究和开发.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.2K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines
437
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
437
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
